Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • JULY 2021 Issue has been successfully launched on 1 July 2021.



Aishwarya Anand and Sajidul Hoque*


Introduction: Several of organ-specific and systemic phenotypes have been added by the COVID-19 pandemic, some previously identified in viral infections, including severe acute respiratory syndrome (SARS) and others that seem to be unique to SARS-coronavirus (CoV)-2. The Coronavirus disease 2019 (COVID-19) pathogenesis is increasingly being recognized where a high number of thrombotic episodes are being recorded which is supported by several coagulation markers. Hence, COVID-19 can be considered as a thrombosis risk factor and as a prothrombotic illness. Management recommendations such as the use of Heparin are driven by increasingly evolving information from scientific observations, autopsy-based results, and extrapolations from in-vitro and ex-vivo experiments and complex modeling; however, several issues remain unanswered and scientific trials that are needed to include proof in most fields have not been conducted. Objective: The following review summarizes emerging findings into pathobiology, mechanism(s), diagnosis, administration, scientific foundations, and proposed or continuing COVID-19-associated coagulopathy clinical trials and use of Heparin in COVID-19 patients. Conclusion: Use of thrombo-prophylactic i.e. Heparin, stratifying high-risk thrombosis patients, particularly the elderly, those with comorbidities and high D-Dimer levels is an important step to prevent thromboembolism in COVID-19 patients.

Keywords: COVID-19, thrombosis risk factor, use of Heparin.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More